{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:01:54Z","timestamp":1777453314233,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravenous hyper-immune anti-cytomegalovirus immunoglobulins (CMV-IG) therapy are licensed for prophylaxis, yet their therapeutic value in established CMV disease remains poorly defined. We aimed to evaluate the clinical and virological impact of adjunctive CMV-IG in combination with standard antiviral therapy in immunocompromised patients with CMV disease, compared with standard antiviral therapy alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a single-center retrospective case-control study at A.O.U. \u201cFederico II\u201d University Hospital, Naples, Italy, including consecutive immunocompromised patients with CMV disease between March 2021 and November 2024. Cases received standard antiviral therapy plus CMV-IG (100 IU kg\n                      <jats:sup>-1<\/jats:sup>\n                      day\n                      <jats:sup>-1<\/jats:sup>\n                      for three consecutive days). Controls received antivirals only.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-four patients were analyzed (15 cases, 19 controls). Thirty-day survival was 93% vs 95% (p=&gt;0.9) and composite outcome (combination of 30-day mortality and clinical response) occurred in 93% vs 90% (p=&gt;0.9) in cases and controls, respectively. Median time-to-virological response in days was achieved 4 vs 7 days (p=&lt;0.001), as was median duration of antiviral therapy in days 12 vs 16 days (p=0.001) and hospitalization 14 vs 19 days (p=0.004) in cases and controls, respectively. Adverse-event rates were low and comparable in the 2 groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world cohort, adjunctive CMV-IG did not affect mortality, but was associated with faster virological clearance and shorter antiviral and hospital courses, without additional toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535261444510","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:52:34Z","timestamp":1776448354000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-5434","authenticated-orcid":false,"given":"Biagio","family":"Pinchera","sequence":"first","affiliation":[{"name":"University of Naples Federico II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"Fusco","sequence":"additional","affiliation":[{"name":"PO A. Cardarelli"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Fotticchia","sequence":"additional","affiliation":[{"name":"University of Naples Federico II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Riccardo","family":"Buonomo","sequence":"additional","affiliation":[{"name":"University of Naples Federico II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Zappulo","sequence":"additional","affiliation":[{"name":"University of Naples Federico II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Schiano Moriello","sequence":"additional","affiliation":[{"name":"University of Naples Federico II"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[{"name":"University of Naples Federico II"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"e_1_3_7_3_2","first-page":"361","article-title":"Effectiveness of Prophylactic Human Cytomegalovirus Hyper-immunoglobulin in Preventing Cytomegalovirus Infection Following Transplantation: A Systematic Review and Meta-Analysis","volume":"12","author":"Markus JB","year":"2022","unstructured":"Markus JB, Baldanti F, Staus A, et al. Effectiveness of Prophylactic Human Cytomegalovirus Hyper-immunoglobulin in Preventing Cytomegalovirus Infection Following Transplantation: A Systematic Review and Meta-Analysis. Life (Basel) 2022; 12: 361.","journal-title":"Life (Basel)"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2024.100875"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10276.1"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913569"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.4.831"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1197828"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0166-9"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad293"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13754"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2021.02.001"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623178"},{"issue":"3","key":"e_1_3_7_15_2","first-page":"SXXX","article-title":"Efficacy Assessment of CMV-Specific Immunoglobulins for CMV Reactivation in High-Risk HSCT Recipients","volume":"46","author":"Gaidamavi\u010dius I","year":"2024","unstructured":"Gaidamavi\u010dius I, Vaitiekus D, Gerbutavi\u010dius R, et al. Efficacy Assessment of CMV-Specific Immunoglobulins for CMV Reactivation in High-Risk HSCT Recipients. Hematol Transfus Cell Ther 2024; 46(Suppl 3): SXXX.","journal-title":"Hematol Transfus Cell Ther"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005374"},{"key":"e_1_3_7_17_2","volume-title":"UK Guideline on Prevention and Management of CMV Following SOT","year":"2024","unstructured":"UK Guideline on Prevention and Management of CMV Following SOT. BTS, 2024."},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(03)00200-6"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9081666"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-025-00081-7"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2017.1398081"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535261444510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535261444510","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535261444510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:26Z","timestamp":1777380806000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535261444510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/13596535261444510"],"URL":"https:\/\/doi.org\/10.1177\/13596535261444510","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"13596535261444510"}}